drugset

drugset / Trial / NCT03163381

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

NCT03163381 ↗

Phase 2 Unknown 40 enrolled Henan Cancer Hospital Jiangsu HengRui Medicine Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Timeline

Start: 2017-04-11
Primary completion: 2017-10-11
Completion: 2019-04-11

Publications

Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	500 mg	Oral

Indications